This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, K. Articles by Shu, H.-K. G. Search for Related Content PubMed PubMed Citation Articles by Xu, K. Articles by Shu, H.-K. G.

EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase–Dependent Activation of the Sp1/Sp3 Transcription Factors in Human Gliomas

Department of Radiation Oncology, Emory University, Atlanta, Georgia

Requests for reprints: Hui-Kuo G. Shu, Department of Radiation Oncology, Emory University, 1365 Clifton Road, Northeast, Building C, Room C-3082, Atlanta, GA 30322. Phone: 404-778-2161; Fax: 404-778-5520; E-mail: hui-kuo{at}radonc.emory.org.

Expression of cyclooxygenase-2 (COX-2) has been linked to many cancers and may contribute to malignant phenotypes, including enhanced proliferation, angiogenesis, and resistance to cytotoxic therapies. Malignant gliomas are highly aggressive brain tumors that display many of these characteristics. One prominent molecular abnormality discovered in these astrocytic brain tumors is alteration of epidermal growth factor (EGF) receptor (EGFR) through gene amplification and/or mutation resulting in excessive signaling from this receptor. We found that EGF-mediated stimulation of EGFR tyrosine kinase in human glioma cell lines induces expression of both COX-2 mRNA and protein. The p38 mitogen-activated protein kinase (p38-MAPK) pathway was a strong downstream factor in this activation with inhibition of this pathway leading to strong suppression of COX-2 induction. The p38-MAPK pathway can activate the Sp1/Sp3 transcription factors and this seems necessary for EGFR-dependent transactivation of the COX-2 promoter. Analysis of COX-2 promoter/luciferase constructs revealed that transcriptional activation of the COX-2 promoter by EGFR requires the Sp1 binding site located at –245/–240. Furthermore, Sp1/Sp3 binding to this site in the promoter is enhanced by EGFR activation both in vitro and in vivo. Enhanced DNA binding by Sp1/Sp3 requires p38-MAPK activity and correlates with increased phosphorylation of the Sp1 transcription factor. Thus, EGFR activation in malignant gliomas can transcriptionally activate COX-2 expression in a process that requires p38-MAPK and Sp1/Sp3. Finally, treatment of glioma cell lines with prostaglandin E2, the predominant product of COX-2 activity, results in increased vascular endothelial growth factor expression, thus potentially linking elevations in COX-2 expression with tumor angiogenesis in malignant gliomas. [Cancer Res 2007;67(13):6121–9]

This article has been cited by other articles:

				F. Loupakis, C. Cremolini, G. Fontanini, I. Stasi, L. Salvatore, and A. Falcone Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 167 - 181. [Abstract] [PDF]

				C.-M. Yang, I-T. Lee, C.-C. Lin, Y.-L. Yang, S.-F. Luo, Y. R. Kou, and L.-D. Hsiao Cigarette smoke extract induces COX-2 expression via a PKC{alpha}/c-Src/EGFR, PDGFR/PI3K/Akt/NF-{kappa}B pathway and p300 in tracheal smooth muscle cells Am J Physiol Lung Cell Mol Physiol, November 1, 2009; 297(5): L892 - L902. [Abstract] [Full Text] [PDF]

				K.-Y. Chang, M.-R. Shen, M.-Y. Lee, W.-L. Wang, W.-C. Su, W.-C. Chang, and B.-K. Chen Epidermal Growth Factor-activated Aryl Hydrocarbon Receptor Nuclear Translocator/HIF-1{beta} Signal Pathway Up-regulates Cyclooxygenase-2 Gene Expression Associated with Squamous Cell Carcinoma J. Biol. Chem., April 10, 2009; 284(15): 9908 - 9916. [Abstract] [Full Text] [PDF]

				R. Caruso, C. Stolfi, M. Sarra, A. Rizzo, M. C. Fantini, F. Pallone, T. T. MacDonald, and G. Monteleone Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3 Blood, April 9, 2009; 113(15): 3512 - 3519. [Abstract] [Full Text] [PDF]

				G. Lurje, F. Nagashima, W. Zhang, D. Yang, H. M. Chang, M. A. Gordon, A. El-Khoueiry, H. Husain, P. M. Wilson, R. D. Ladner, et al. Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab Clin. Cancer Res., December 1, 2008; 14(23): 7884 - 7895. [Abstract] [Full Text] [PDF]

				J. A. Schwartzbaum, A. Ahlbom, S. Lonn, B. Malmer, A. Wigertz, A. Auvinen, A. J. Brookes, H. Collatz Christensen, R. Henriksson, C. Johansen, et al. An International Case-Control Study of Interleukin-4R{alpha}, Interleukin-13, and Cyclooxygenase-2 Polymorphisms and Glioblastoma Risk Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2448 - 2454. [Abstract] [Full Text] [PDF]